| Primary | Hospital Admission Rate at Initial Episode of Care | | Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. | Posted | | Count of Participants | | Participants | | 44 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| | | Title | Denominators | Categories |
|---|
| | |
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | Fisher Exact | | <0.001 | | Odds Ratio (OR) | 0.289 | | | 2-Sided | 95 | 0.156 | 0.532 | | | | | Superiority | | |
|
| Secondary | Number of Total Admitted Hospital Days | Number of days during the initial hospitalization (for those initially hospitalized) and all other hospitalizations | FAS population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period. | Posted | | Mean | Standard Deviation | Days | | 44 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Total Length of Stay in Emergency Department (ED) During the Initial Episode of Care | Time spent in ED in hours from triage to release (either admitted to the hospital, admitted to observation, or released to home) | Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. | Posted | | Mean | Standard Deviation | Hours | | Initial Care: 14 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Number of Participants With Infection-related Major Surgical Interventions That Required Operating Room Time | Number of all major surgical interventions unexpected or expected that required operating room time | Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period. | Posted | | Count of Participants | | Participants | | 44 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Number of Infection-related Total Admitted Hospital Days | | Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period. | Posted | | Mean | Standard Deviation | Days | | 44 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Number of Participants With Infection-related Hospitalizations | Number of days of hospitalization during the initial hospitalization (for those initially hospitalized) and all other infection-related hospitalizations | Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period. | Posted | | Count of Participants | | Participants | | 44 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Number of Participants With Infection-related Hospitalizations During Initial Care and Follow-up That Resulted in Admission to Intensive Care Unit | | Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period. | Posted | | Count of Participants | | Participants | | 44 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Number of Participants With All Cause Hospitalizations in the 30 Days Post Discharge From the Hospital or Release From the ED | | Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period. | Posted | | Number | | Participants | | Follow-up: 30 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Number of Participants With Infection-related Emergency Department (ED) Visits | | Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period. | Posted | | Number | | Participants | | 44 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Number of Participants With Infection-related Outpatient Healthcare Visits | | Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period. | Posted | | Number | | Participants | | 44 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Use of a Peripherally-Inserted Central Catheter (PICC) Line or Central Line to Administer Antibiotic Therapy | | Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period. | Posted | | Number | | Participants | | 44 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Number of Participants With Infection-related Healthcare Visits Due to PICC Line or Central Line Used to Administer Antibiotic Therapy | | Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period. | Posted | | Count of Participants | | Participants | | 44 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Number of Participants With Serious Adverse Events (SAEs) | | Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion | Posted | | Count of Participants | | Participants | | 44 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Overall Health | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Wait in Emergency Room | Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. | FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. | Posted | | Mean | Standard Deviation | scores on a scale | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Hospitalization | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Satisfaction With Hospital Stay | Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. | FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. 63 and 27 patients had a hospital stay in the usual care group and new critical pathway group, respectively. | Posted | | Mean | Standard Deviation | Scores on a Scale | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Factors for Dissatisfaction With Your Hospital Stay | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. Patients may have checked multiple responses. | Posted | | Number | | Participant | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Received IV Antibiotic Therapy for Skin Infections | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Satisfaction With Receiving IV Antibiotic Therapy | Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. | 119 & 124 patients provided any survey data in the usual care group & new critical pathway group; 87 & 119 patients received IV antibiotic therapy in the usual care group & new critical pathway group; 86 and 119 patients answered this question in the usual care group & new critical pathway group, respectively. | Posted | | Mean | Standard Deviation | Scores on a Scale | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Factors Contributing to Satisfaction With Receiving IV | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. Patients may have checked multiple responses. | Posted | | Number | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Factors Contributing to Dissatisfaction With Receiving IV | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. Patients may have checked multiple responses. | Posted | | Number | | Participants | | 14 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: IV Therapy Hindering Normal Activities of Daily Living | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | 119 & 124 patients provided any survey data in the usual care group & new critical pathway group; 87 & 119 patients received IV antibiotic therapy in the usual care group & new critical pathway group; 87 and 118 patients answered this question in the usual care group & new critical pathway group, respectively | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Concerned About Receiving Your IV Therapy | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | 119 & 124 patients provided any survey data in the usual care group & new critical pathway group; 87 & 119 patients received IV antibiotic therapy in the usual care group & new critical pathway group; 87 and 118 patients answered this question in the usual care group & new critical pathway group, respectively. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Satisfied With the Number of IV Infusions Received Per Day | Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. | 119 & 124 patients provided any survey data in the usual care group & new critical pathway group; 87 & 119 patients received IV antibiotic therapy in the usual care group & new critical pathway group; 85 and 118 patients answered this question in the usual care group & new critical pathway group, respectively | Posted | | Mean | Standard Deviation | Scores on a scale | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Satisfaction With the Average Time to Administer Each IV | Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible. | 119 & 124 patients provided any survey data in the usual care group & new critical pathway group; 87 & 119 patients received IV antibiotic therapy in the usual care group & new critical pathway group; 85 and 118 patients answered this question in the usual care group & new critical pathway group, respectively. | Posted | | Mean | Standard Deviation | Scores on a Scale | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Time to Travel to Appointments to Receive IV | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | 119 & 124 patients provided any survey data in the usual care group & new critical pathway group; 87 & 119 patients received IV antibiotic therapy in the usual care group & new critical pathway group; 86 and 118 patients answered this question in the usual care group & new critical pathway group, respectively. | Posted | | Count of Participants | | Participants | | 14 days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Average Time to be Seen by a Healthcare Provider | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | 119 & 124 patients provided any survey data in the usual care group & new critical pathway group; 87 & 119 patients received IV antibiotic therapy in the usual care group & new critical pathway group; 86 and 118 patients answered this question in the usual care group & new critical pathway group, respectively. | Posted | | Count of Participants | | Participants | | 14 days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Healthcare Setting Preferred if Treated Again for a Skin Infection With IV | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group; 116 and 123 patients answered this question in the usual care group & new critical pathway group, respectively. | Posted | | Count of Participants | | Participants | | 14 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Factors Contributing to Preference for Outpatient Care | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. Patients may have checked multiple responses. | Posted | | Number | | Participants | | 14 Days | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Regimen Preferred if Treated Again for a Similar Skin Infection With IV | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group; 117 and 121 patients answered this survey question in the usual care group & new critical pathway group, respectively. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Time Willing to Spend Receiving Each IV | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group; 117 and 123 patients answered this survey question in the usual care group & new critical pathway group, respectively. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Satisfaction With Care: Find Value in a Physician | Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported). | FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group; 115 and 123 patients answered this survey question in the usual care group & new critical pathway group, respectively. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Work and Productivity Loss as Assessed Through the Work Productivity and Activity Impairment Questionnaire | Number of days with lost/reduced productivity during follow-up, as measured with Work Productivity and Activity Impairment (WPAI) Questionnaire | FAS population. 119 and 123 patients provided any survey data in the usual care group and the new critical pathway group; 53 and 48 patients completed all survey questions in the usual care group and new critical pathway group, respectively. 61 and 56 were employed. | Posted | | Mean | Standard Deviation | Percentage | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |
| Secondary | Patient Health-related Quality of Life (HRQoL) Assessed by the Short Form 12 (SF-12) 12-Item Patient Questionnaire | The SF-12 yields a physical and a mental health component summary score (referred to as physical component summary score [PCS] and mental component summary score [MCS]). The PCS and MCS follow a t-score distribution, i.e. mean of 50 and standard deviation of 10 in the general US population, meaning all scores above or below 50 are above and below the average, respectively, in the US general population. | FAS population. 119 and 122 patients provided any and all survey data in the usual care group and the new critical pathway group, respectively. | Posted | | Mean | Standard Deviation | Score on a Scale | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Usual Care | Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI. | | OG001 | New Critical Pathway | The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI. |
| |